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A B S T R A C T
Background: Chemical UV filters are common components in sunscreens and cosmetic products and used to
protect the skin against harmful effects of sunlight like sunburn. However, the effectiveness of sunscreens in the
prevention of skin cancer is in some parts still controversial. Meanwhile, questions about negative effects of the
chemical UV filters on human health arise and request an effective risk assessment. Real-life exposure data in
humans after application of these products are still rare. Thus, we explored whether and to what extent UV filters
are absorbed through the skin into the human body.
Material and methods: Plasma and urine samples from 20 healthy volunteers were collected before, during and
after a real-life exposure scenario (1st application: 2mg/cm2; 2nd and 3rd (after 2 and 4 h): 1 mg/cm2 each)
using a commercial sunscreen formulation for one day. These samples were analyzed for their content of the
currently prominent UV filters octocrylene and avobenzone as well as 2-cyano-3,3-diphenylacrylic acid (CDAA)
as the main octocrylene metabolite by using different liquid chromatography electrospray-ionization tandem
mass spectrometric procedures.
Results: Following dermal sunscreen exposure, avobenzone, octocrylene and CDAA reached concentrations up to
11 μg/L, 25 μg/L and 1352 μg/L in plasma. In urine detection rates of avobenzone and octocrylene were low
while CDAA showed a high detection rate and reached up to 5207 μg/g creatinine. Kinetic models could be fitted
for octocrylene and CDAA in plasma and CDAA in urine. Concentration peaks were reached between 10 and 16 h
after first application and half-life periods were in the range of 1.5 to 2 days. The lipophilic UV filter octocrylene
and its metabolite CDAA showed a much slower elimination than other more hydrophilic UV filters.
Concordantly, the metabolite CDAA in particular showed a markedly increased renal excretion over the whole
sampling period and indicated high internal exposure to OC.
Discussion: Real-life sunscreen usage leads to considerable bioavailability of organic UV filters and their meta-
bolites which is rarely seen for other environmental exposures. A combined monitoring of the parent compound
and its metabolites is important to fully address internal exposure to the UV filter in humans. Considering the
kinetic profiles a prolonged systemic release due to depot formation in skin and a potential accumulation
through multi-day exposure is presumed. High in-vivo loads call for a critical toxicological assessment of the UV
filters and their metabolites.
1. Introduction
UV Filters are widely used throughout the world in cosmetic and
personal care products as well as in plastics and industrial products for
their UV-absorbing properties. They either protect the human skin
against deleterious effects of UV radiation or prevent photodegradation
of the products itself (Gago-Ferrero et al., 2012; Manova et al., 2013;
Uter et al., 2014; Wang et al., 2016). Two organic UV filters commonly
used nowadays are avobenzone (AVO; CAS No. 70356-09-1; molecular
weight: 310.4 g/mol) and octocrylene (OC; CAS No. 6197-30-4;
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molecular weight: 361.5 g/mol) (Kerr, 2011; Manova et al., 2013; Uter
et al., 2014). Due to their widespread use with continuous anthro-
pogenic input into the ecosystems organic UV filters have been detected
in a wide array of biota such as sediments, surface and marine water,
fish and mussels and even in marine mammals, thus demonstrating
bioaccumulation in the food chain (Balmer et al., 2005; Gago-Ferrero
et al., 2012; Baron et al., 2013; Gago-Ferrero et al., 2013; Apel et al.,
2018a; Apel et al., 2018b; Vidal-Linan et al., 2018).
Detrimental and adverse effects have not only been described for
aquatic organisms (Ozaez et al., 2016b; Campos et al., 2017; Giraldo
et al., 2017; Li et al., 2018) but also in mammals and humans. Besides
the possible causation of (photoallergic) contact dermatitis in some
individuals (de Groot and Roberts, 2014) especially endocrine dis-
rupting effects (Witorsch and Thomas, 2010; CEHOS, 2013; Gilbert
et al., 2013; Wang et al., 2016) as well as neurotoxic and metabolic
disrupting potential (Ruszkiewicz et al., 2017; Ahn et al., 2019) have
been described. However, those assumptions are mostly based on data
by in-vitro studies and their in-vivo relevance remains to be clarified.
For example, in-vitro studies on OC showed affinity to various hor-
monal receptors or effects attributed to such capacities (Kunz and Fent,
2006; Balazs et al., 2016; Ozaez et al., 2016a; Zhang et al., 2016).
However, it is unclear how these receptor interactions translate to a
possible adverse outcome in-vivo as a reproductive and developmental
toxicity could not be confirmed in rat studies (European Chemicals
Agency). Concerning AVO, in-vitro data indicated that a possible en-
docrine disruption potential might be present but no uterotrophic effect
could be demonstrated in-vivo (Schlumpf et al., 2001; Schreurs et al.,
2005; CEHOS, 2013). Furthermore, AVO has been suspected to be a
human obesogenic chemical as it significantly promoted adipogenesis
in in human bone marrow mesenchymal stem cells (Ahn et al., 2019).
Health concerns become especially relevant considering that sunscreen
products are frequently applied around the world (Mancuso et al.,
2017; Seite et al., 2017) including particularly vulnerable or susceptible
individuals such as pregnant women and children. The annual pro-
duction volume of sunscreen has increased significantly lately. In Ger-
many the production volume almost doubled over the last decade
(Destatis, 2018).
The application of UV filters directly on the skin needs considera-
tion in human exposure assessment as the dermal exposure is probably
the most relevant exposure route of UV filters for humans both in daily
life and in outdoor work. In-vitro penetration into the stratum corneum
and in some cases even through the skin has been shown (Jiang et al.,
1999; Potard et al., 2000; Chatelain et al., 2003; Iannuccelli et al.,
2008; Montenegro et al., 2008; Scalia et al., 2011; Montenegro and
Puglisi, 2013). Even more importantly, recent studies have reported
systemic absorption of organic UV filters in humans after sunscreen
application. Under a maximum use scenario concentrations of AVO and
OC in plasma exceeded threshold levels set forth by the US Food and
Drug Administration (FDA) for waiving nonclinical toxicology studies
(Matta et al., 2019). In support of these findings, an increasing excre-
tion of specific OC metabolites in urine after a dermal sunscreen ap-
plication in one volunteer has been described (Bury et al., 2019) as well
as higher background levels in persons who had used sunscreen in the
previous 5 days as opposed to nonusers (Bury et al., 2018).
These studies suggest that the currently often used organic UV filters
AVO and OC reach the circulatory system in humans after sunscreen
exposure and a dermal exposure to those UV filter might contribute
substantially to their overall burden in humans. However, reliable data on
the extent of dermal penetration and in-vivo fate under real-life condi-
tions are still limited and need further addressing. Accurate risk assess-
ment needs to be based on sound exposure data. Therefore, the study
objective was to determine the systemic availability and renal elimination
of AVO, OC and the main OC metabolite after a whole body dermal
sunscreen exposure under real-life conditions in humans. A particular
focus was placed upon concurrent monitoring of both parent compound
and metabolite as well as determination in plasma and urine samples.
2. Materials & methods
2.1. Study design
A commercial sunscreen lotion2 with a sun protection factor (SPF)
of 30 containing three currently often used organic UV filters and ti-
tanium dioxide as active ingredients was selected for our study. Besides
AVO and OC the sunscreen also contained 2-ethylhexyl-salicylate (EHS)
as a more hydrophilic organic UV filter whose urinary excretion has
been investigated as well and is reported elsewhere (Hiller et al., 2019).
The concerted study protocol is described in detail below.
For the real-life exposure all volunteers spent one day outside
dressed in bathing clothes in a separated, partly shaded park area of the
university on a summer day in July 2017. There were no requirements
for the participants concerning the stay in the sun or shade with both
options readily available throughout the day. The weather was in parts
lightly overcast in the morning but mostly sunny (9 h of sunshine ac-
cording to the meteorological data for the day), reflecting a typical
German summer day. Temperatures reached a maximum of 27.4 °C in
the afternoon with relative ambient humidity being around 50%. Food
and beverages ad libitum were provided by the organizing team during
the exposure period. Food items were selected with a preferred usage of
cutlery in mind to minimize hand-mouth contamination and partici-
pants were instructed to avoid hand-mouth contamination.
The individual amount of sunscreen was calculated using the body
surface area (BSA) and a skin dose of 2mg sunscreen per cm2 BSA. This
is the testing dose used to obtain the stated SPF of a sunscreen product
according to ISO 24444:2010 test guideline (ISO, 2010). Therefore, the
volunteers received between 30.8 and 41.2 g of sunscreen for the initial
application. After the first application the volunteers received half of
the initial amount each for a second and a third dosing of sunscreen 2
and 4 h after the initial application to account for the recommended
reapplication of sunscreen (Diffey, 2001; Petersen and Wulf, 2014;
Matta et al., 2019).
After collecting baseline samples (t0) all subjects were given their
first individualized sunscreen portion and asked to apply all of it by
themselves for the start of the exposure period. Subjects wore bikinis or
swim trunks and applied the sunscreen to the uncovered skin, i.e. all
areas outside the normal swimwear but sparing lips, eyes, hairy scalp
and plantae. Therefore the amount of body surface covered with
sunscreen amounted to approximately 75 to 80% gauging by the rule-
of-nines. The subjects stayed outside at the university's premises until
8.5 h after initial application. Afterwards, the subjects were asked to go
home and shower promptly using a standardized shower gel to end
external sunscreen exposure after 9 h.
Blood samples were drawn during the exposure period after 1.75,
3.75, 5.75 and 7.75 h as well as after 24, 48 and 72 h. The blood
samples were centrifuged and plasma was frozen at −20 °C within a
day until analysis. All excreted urine was collected in separate portions
with a clean polypropylene measuring cup containing up to 1 L and
marked every 10mL to obtain complete separate urine voids during the
first 24 h. One-hour-intervals were requested during the on-site ex-
posure period starting 30min after the first application. Afterwards the
collection of complete fractioned urine samples was continued by the
study subjects without time restrictions for the remaining 15 h. For
follow-up, complete morning urine samples were requested for another
2 Ingredients: Aqua, Octocrylene, Alcohol, Glycerin, C12–15 Alkyl Benzoate,
Ethylhexyl Salicylate, Titanium Dioxide (Nano), Butyl
Methoxydibenzoylmethane, Propylheptyl Caprylate, Stearyl Dimethicone, VP/
Hexadecene Copolymer, Panthenol, Butyrospermum Parkii Butter, Parfum,
Tocopheryl Acetate, Silica, Ethylhexylglycerin, Acrylates/C10–30 Alkyl
Acrylate Crosspolymer, Carbomer, Sodium Hydroxide, Xanthan Gum, Disodium
EDTA, Dimethicone, Linalool, Limonene, Benzyl Salicylate, Eugenol,
Citronellol, Coumarin, Tocopherol.
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6 days. The excreted volume and the sample time of each urine sample
were recorded by the participants on a documentation form. An aliquot
was immediately bottled in a sterile polypropylene 100mL container
and frozen until analysis. An exact timeline protocol with sampling time
points as well as the exposure sequence can be found in the supple-
mentary material (Fig. S3).
The study design, sample collection and data processing were ap-
proved by the local ethics committee of the University of Erlangen-
Nürnberg (Re.-No. 122_17B; 17.05.2017). Informed written consent
was obtained from each participant prior to inclusion.
2.2. Study collective
The following exclusion criteria were defined for the recruitment of
the study collective to minimize concurrent exposure and health risks:
• Age of< 18 or> 50 years• current or previous malignant or semi-malignant skin tumor• autoimmune or genetic disease with elevated UV sensitivity thereof• use of UV sensitizing/phototoxic medication• known allergy against sunscreen products• known polymorphic light eruption (so-called “sun allergy”)• pregnant or lactating women• use of sunscreen products or cosmetic products containing chemical
UV filters in the week before and after the exposure• use of insect repellents during and in the 3 days before and after the
exposure
28 volunteers (n=14 men; n= 14 women) who complied with the
above stated criteria were recruited primarily from the students of the
University of Erlangen-Nürnberg, paying attention to a balanced sex
distribution.
To calculate the individual BSA with the formula of DuBois (DuBois
and DuBois, 1989) their anthropometric data were measured. Fur-
thermore skin blemishes such as scratches were clinically inspected and
documented as a possible factor of influence regarding skin penetration.
Skin and eye color as well as the subject's reports of how their skin
responds to the sun were assessed to determine the skin pigmentation
type according to Fitzpatrick (1988).
The consumption of beverages was not restricted during the ex-
posure period due to the warm weather conditions. Therefore, some-
times a high overall urinary excretion was observed. To ensure an ac-
ceptable sample quality eight candidates with>4000mL urine
excretion during the first 8.5 h after first application or> 5000mL
within 24 h, i.e. highly unphysiological parameters, were excluded
before chemical analysis of the samples.
2.3. Chemical materials and analysis
The UV filter concentrations of the chosen sunscreen were 2.34%
AVO and 10.85% OC, determined by the Bavarian State Office for
Health and Food Safety. The two lipophilic UV filters OC and AVO were
selected as the primary analytical targets. As recent research identified
specific metabolites for OC, and 2-cyano-3,3-diphenylacrylic acid
(CDAA) as one of those could be identified as the main metabolite re-
presenting 45% of the OC dose after oral administration (Bury et al.,
2018, 2019), CDAA was included in the analyses. The parent com-
pounds and the metabolite were analyzed in plasma by liquid chro-
matography electrospray-ionization tandem mass spectrometry
(LC–MS/MS) and in urine by using two-dimensional LC/LC–MS/MS
procedures as described elsewhere (Klotz et al., 2019). The limits of
detection (LOD) were 1.1 μg/L plasma and 1.5 μg/L urine for AVO,
1.6 μg/L plasma and 1.44 μg/L urine for OC and 6.5 μg/L plasma and
0.45 μg/L urine for CDAA. Creatinine content of the urine samples was
determined photometrically according to the Jaffe's method (Larsen,
1972).
2.4. Data processing and statistical analysis
The initial results of the analysis were obtained in μg/L for both
matrices. However, to account for different urinary dilutions, absolute
urine concentrations were subsequently converted to a creatinine-re-
lated concentration. Additionally, the absolute urine concentration in
μg/L was multiplied with the excreted sample volume to calculate the
total cumulative excreted amount of the analytes during the fractioned
urine sampling period, therefore arriving at a creatinine and dilution
independent result for the first 24 h.
Plasma samples below the LOD were replaced by half the LOD.
Urine samples with concentrations below the LOD were factored in the
kinetic calculations with 1.25 μg AVO/g, 1.22 μg OC/g and 0.23 μg
CDAA/g creatinine.
The relative renal recovery (RRR) was calculated by dividing the
cumulative excretion amount in the first 24 h by the amount of analyte
applied by each individual.
Plasma and urine concentrations as well as the cumulative excreted
amounts were plotted as a function of time using ggplot2 graphics
(Wickham, 2016). Mean curves were fitted using generalized nonlinear
least-squares, accounting for heteroscedasticity via the power variance
function and correlated errors via a continuous-time AR(1) structure for
repeated measurements (Pinheiro and Bates, 2000). A log-normal shape
was assumed for urinary and blood concentration kinetics, whereas a
log-logistic growth curve was fitted to the cumulative excretion
amounts. Confidence intervals for fitted curves and derived statistics
were computed by parametric bootstrap, including for the peak time
and concentration as well as for the partial area under the curve (AUC)
above baseline to estimate the relative excreted fraction over 24 h.
Plasma and excretion terminal half-lives (t1/2) were calculated with
the formula t1/2= ln2 /│kel│ using the slope (kel) of the linear re-
gression between ln-transformed concentrations and times assuming a
first-order elimination process as described previously (Göen et al.,
2016). kel is defined as the elimination rate constant. Due to depot
formulation this half-life is not an elimination half-life, but a terminal
half-life. A mixed-effects model with individual-specific deviations from
the global intercept and slope was used to account for repeated mea-
surements.
Rank-based tests for independent samples (Mann-Whitney-U or in
case of more than two levels Kruskal-Wallis) were used to explore
possible influence factors on bioavailability and excretion rates.
Associations between plasma and urine concentrations were analyzed
by linear regression analysis using Pearson correlation.
IBM® SPSS® Statistics Version 25, OriginLab Origin® 2018b and the
statistical programming environment R 3.5.2, R Core Team, 2018, R
Foundation for Statistical Computing, Vienna, Austria. (www.R-project.
org/) were used for statistical analysis.
3. Results & discussion
Twenty-eight volunteers (n= 14 men; n= 14 women) were in-
itially recruited, however, as described in the study protocol, eight in-
dividuals were excluded from analytical analysis on account of their
high excreted urine volumes. With 9 women and 11 men included, the
final study collective had a fairly balanced sex distribution. The sub-
ject's characteristics showed a narrow age span but considerably dif-
ferent anthropometrics (Table 1). Skin type I according to Fitzpatrick
(1988) was seen in 5%, skin type II in 25%, skin type III in 60% and skin
type IV in 10%.
For all analytes the baseline load in plasma was below or close to
the LOD, especially AVO was not detectable at baseline at all. However,
systemic availability of all analytes increased following topical sunsc-
reen application (Fig. 1a–c). AVO could not be detected in plasma in
three subjects at any time. For OC and CDAA the data in plasma were
sufficient to fit an overall kinetic model. The peak concentrations of OC
and CDAA in plasma were reached 10.0 h and 14.5 h, respectively, after
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the first dermal application. Especially for CDAA the 72 h plasma levels
were still markedly higher than baseline showing prolonged systemic
availability after dermal exposure. Also its parent compound OC
showed a systemic occurrence over the whole assessment period. Based
on the kinetic models plasma elimination rate constants (kel) of 0.016
and 0.019 h−1 and terminal plasma half-lives (t1/2) of 44 and 36 h were
calculated for the 1st phase period from 24 to 72 h after first application
(Table 2). For AVO only the descriptive statistics for each sampling
point could be compared and yielded the highest plasma median at
7.75 h after the first application. The individual peak concentrations of
AVO were reached within the time frame of 1.75 to 24 h. Considering
the available literature data for AVO concentrations in plasma and the
LOD of our analytical method of 1.1 μg/L, it is not surprising that we
could not detect AVO in the samples of three subjects at any time as the
lowest observed AVO concentrations on the first day of a maximum use
trial of different sunscreens formulations laid between 0.4 and 1.0 μg/L
(Matta et al., 2019).
Complete 24 h urine sampling over the first observation period was
proven by calculating the cumulative creatinine excretion over 24 h
(Table 1) and comparing that to the expected sex and weight specific
reference value (Forni Ogna et al., 2015) . Complete sampling was as-
sumed when the cumulative creatinine excretion was above the re-
spective lower reference value. This was achieved by all subjects. The
male volunteers showed a significantly (p < 0.001) higher creatinine
excretion per day (MD: 1737mg; Min–Max: 1349–2257mg) than
women (MD: 1155mg; Min–Max: 768–1557mg).
Neither AVO nor OC was detected in urine before the sunscreen
exposure, while low concentrations of CDAA were found in baseline
urine. Following sunscreen application, urinary excretion of the un-
metabolized UV filters as well as CDAA was demonstrated. AVO and OC
were detected in<20% of the samples and were mostly close to the
detection limits of our methods. Additionally, even in cases in whom it
was possible to quantify AVO and OC, respectively, intra-individual
variability between the sampling points was high. Therefore, the
identification of consistent excretion profiles over time or calculation of
the cumulative excreted amount was not possible for both parent
compounds. Nonetheless, the vast majority of samples where AVO and
OC could be quantified were collected within the first 24 h following
dermal application (supplementary material Fig. S4). This timeframe of
quantifiable excretion coincided with the plasma availability and in-
dicates reasonable resorption and elimination timelines.
However, the OC metabolite CDAA showed a high urinary excretion
after sunscreen application and allowed the derivation of urinary
elimination kinetics, the calculation of the total cumulative excreted
amount over the first 24 h as well as the relative 24 h excretion fraction
(Fig. 2, Table 3). Following topical sunscreen application, a progressive
increase of CDAA excretion was found until the maximum urinary
concentrations were reached around 16 h after the first application.
Similar to the prolonged plasma kinetics, a significantly elevated ur-
inary excretion of CDAA was present over the whole 7 day sampling
period (Fig. 2a) and yielded a comparatively long terminal half-life of
38 h (1st phase, period: 22.5–168 h after first application; supplemen-
tary material Fig. S2). Comparison of the AUC fractions showed that
only 32.9% (95% CI: 30.9–35.0) of the total 7 day urinary CDAA
amount was excreted within 24 h after first application and 63.3%
(95% CI: 60.7–66.2) within 48 h. Nonetheless, the absolute cumulative
CDAA amount excreted over 24 h reached up to 4761 μg which corre-
sponds to 6904 μg octocrylene.
The resorption and elimination timelines of AVO and OC and its
metabolite found in our study reflect the typical kinetic profiles ex-
pected by the dermal exposure route. An uptake from transdermal ab-
sorbed substances into the body may be buffered by a subcutaneous or
cutaneous reservoir and lead to delayed but continuous systemic
availability and long plasma and urinary elimination periods even after
cessation of the external exposure. This has already been described for
transdermally absorbed substances (Rom and Markowitz, 2007;
Khemiri et al., 2018; Stoeckelhuber et al., 2018). Further support for
this assumption can be found in literature comparing the renal excre-
tion kinetics from oral OC dosage (Bury et al., 2018; Bury et al., 2019):
After oral administration of OC, the maximum urinary metabolite
concentrations for CDAA were found much earlier after 4.2 h and t1/2
was 5.7 h for the first phase elimination, and 16 h of the 2nd phase
elimination, respectively. The same study group also described an in-
creasing excretion of OC metabolites in the urine of one volunteer after
dermal sunscreen application (Bury et al., 2019). In principle, the
findings of that study were also consistent with transdermal uptake,
even though the recovered amounts and kinetic considerations should
be interpreted with caution due to very different exposure conditions
(36-times lower OC exposure; shorter exposure duration; missing real-
life conditions with heat and sunlight).
The long terminal half-lives of OC and CDAA in plasma and CDAA in
urine and the relatively low 24 h and 48 h urinary elimination fractions
of CDAA indicate potential accumulation in the human body if exposure
is repeated on several successive days – as typical for a holiday or an
outdoor-work setting. Even though the data basis for AVO in our study
is less robust than that of OC, the observed kinetics and the similar
lipophilic chemical structure suggest potential bioaccumulation of
AVO, too.
Accordingly, a recently published study on plasma concentrations of
active sunscreen ingredients under maximum use conditions demon-
strated pharmacokinetic profiles consistent with drug accumulation due
to increasing maximum concentrations and AUC over a 4-day exposure
period for both AVO and OC (Matta et al., 2019). Although the study
focused solely on the parent compounds and the matrix plasma, the
findings further support our hypothesis of potential bioaccumulation.
An implied serrated increase from day 1 to day 4 could be seen in the
plasma profiles of all four tested sunscreen products; although the
geometric mean of the time to maximum concentration was found to be
around 68–77 h for AVO and 55–75 h for OC, i.e. before the end of the
4-day exposure period, possibly indicating saturatic effects for repeated
exposure. The kinetics observed following multi-day exposure are in
accordance with the results of our study but raise the question of lim-
iting factors on accumulation due to a saturated intradermal depot
formation. When comparing our plasma concentrations to the con-
centrations found by Matta et al. (2019) the methodical differences
from the chosen measures of central tendencies (median vs. geometric
mean) should be considered. Nevertheless, the absolute highest plasma
concentrations of AVO (9.3 μg/L) and OC (20.4 μg/L) found by Matta
et al., 2019 were somewhat below the highest concentrations seen in
some subjects in our study (AVO 11.7 μg/L; OC 25.0 μg/L) although our
total applied sunscreen amount was lower and exposure duration was
shorter. This might be explained by one major limitation of the study by
Matta et al. (2019), which the authors also pointed out themselves: The
sunscreens were applied without exposure to heat or direct sunlight,
i.e., not under typical “real-life” conditions.
Exposure conditions such as solar UV radiation are likely to influ-
ence dermal penetration. It has, for instance, been reported that
Table 1
Subject characteristics and applied amount of test compounds.
Mean SD Min Median Max
Age [year] 24.5 2.6 19 24 31
Height [m] 1.73 0.08 1.56 1.74 1.88
Weight [kg] 70.5 10.6 54.1 70.1 93.3
Body surface area [m2] 1.83 0.16 1.58 1.85 2.06
Sunscreen applied [g] 73.1 6.4 63.2 73.8 82.4
AVO applied [g] 1.7 0.2 1.5 1.7 1.9
OC applied [g] 7.9 0.7 6.9 8.0 8.9
Total creatinine excretion over first 24 h [mg] 1485 389 768 1502 2257
SD= standard deviation; Min=minimum, Max=maximum.
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simulated sunlight exposure via UV radiation for 16min increased the
penetration of OC into the stratum corneum 1.4-fold and into the epi-
dermis 5.7-fold in diffusion cell experiments (Duracher et al., 2009).
This could be due to the irradiation itself interacting with the structure
of the substance but also due to direct or indirect temperature effects on
the skin and underlying structures such as increased regional blood
flow. An augmented skin penetration through increased temperatures
had been repeatedly reported (Klemsdal et al., 1992; Emilson et al.,
1993). On the other hand, photodegradation of the UV filters in the
applied sunscreens due to UV radiation can also be discussed, but seems
of more limited importance, as OC was found to be stable under UV
exposure in a variety of formulations while AVO showed some de-
gradation (Freitas et al., 2015) but can still be stabilized by other in-
gredients including OC (Hexsel et al., 2008; Nash and Tanner, 2014).
Moreover saturatic effects of a skin depot could hinder a further pe-
netration from multidays exposure with a practically infinite exposure
Fig. 1. Pharmacokinetic plasma profiles of avobenzone (a), octocrylene (b) and CDAA (c). For avobenzone the descriptive statistics are depicted, each square and
vertical line represents the geometric mean and 1.5 times Standard error of 20 individuals; vertical lines represent the median and are connected through the dotted
line. For octocrylene (b) and CDAA (c) the combined log-normal-models with 95% pointwise confidence bands and 95% confidence intervals for the peak time and
concentration are depicted. SE= standard error.
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dose. Therefore, it is possible that an exposure scenario without real
outdoor conditions and sunlight will misjudge the systemic load ex-
perienced in real-life in either way.
The overall penetrating amount that becomes systemically available
of the two analyzed lipophilic UV filters might also be underestimated
in the FDA study by only evaluating the unmetabolized substances. As
seen in the present study, considerable quantities of the main OC
metabolite CDAA can be found after dermal OC exposure, whereas OC
is only measurable in small amounts in the compartments plasma and
urine (Tables 2 & 3). Quantitative comparison of AUCs over 72 h from
the kinetic plasma models of OC to CDAA showed a ratio of 1:62
(Fig. 3). Nevertheless, a higher availability of OC in other body com-
partments such as fat tissue or a subcutaneous or cutaneous reservoir
may be considered as well and needs addressing in further studies.
Table 2
Key figures and toxicokinetic parameters for plasma data.
AVO OC CDAA
Median Max. Median Max. Median Max.
Concentration at t0 [μg/L] < LOD <LOD 1.7 9.1 7.8 21.9
Max. observed concentration [μg/L] 4.0 11.3 11.7 25.0 570.2 1351.7
Concentration at 72 h [μg/L] < LOD 1.8 3.1 13.4 198.9 385.5
tmax [h] n.d. 10.0
(95% CI: 6.9–13.4)
14.5
(95% CI: 13.2–15.9)
kel [h−1] n.d. 0.016
(95% CI: 0.007–0.025)
0.019
(95% CI: 0.016–0.022)
Half-life t1/2 [h] n.d. 43.9
(95% CI: 19.0–68.7)
36.1
(95% CI: 31.0–41.2)
Subjects with analyte detected [%] 85 100 100
Samples below LOD [%] 57 17 6
LOD [μg/L] 1.1 1.6 6.5
n.d.= not determined, LOD= limit of detection, Max.=maximum; tmax= time of peak concentration after first application.
Fig. 2. Time course of the urinary excretion (a) and cumulative excreted amount (b) of CDAA after dermal exposure with combined log-normal-model (a) and
combined log-logistic growth model (b) with heteroscedastic and correlated errors. 95% confidence intervals based on parametric bootstrap.
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Furthermore other elimination routes such as clearing via bile and feces
are deceivable as well and would contribute to an underestimation of
the penetrated amount.
In this respect, further consideration should be given to the re-
spective concentration profiles and pharmacokinetic data of OC and
CDAA in plasma and urine. When their resorption and elimination
timelines are simultaneously depicted (Fig. 3) some observations might
provide further insight into the metabolization process: The OC meta-
bolite CDAA showed a slightly delayed peak time in plasma (14.5 h vs.
10.0 h, with overlapping confidence intervals) and a slightly shorter
terminal half-life (36.1 h vs. 43.9 h) compared to the parent compound.
The kinetics of CDAA in plasma were confirmed by similar urinary
elimination kinetics with peak time at 15.9 h and half-life of 37.6 h. The
congruence of the kinetics of parent compound and metabolite supports
the hypothesis that CDAA originates mainly from a hepatic metabolism
of systemic available OC, but not from the absorption of CDAA after
degradation of OC in the skin.
The urinary CDAA excretion was significantly associated with CDAA
plasma levels (Fig. 4; R2= 0.707). This effect proved to be strongest
during the exposure period, while plasma and urinary levels show a
higher variability after cessation of exposure (Pearson-correlation at
2 h: R2= 0.882, p < 0.001; at 4 h: R2= 0.766, p < 0.001; at 6 h:
R2=0.616, p < 0.001; at 8 h: R2=0.643, p < 0.001; at 48 h:
R2=0.128, p=0.122; at 72 h: R2=0.213, p=0.04).
Additionally we evaluated sex and skin type as factors possibly in-
fluencing skin penetration. Distinctive inter-individual variations in the
recovery rates were found in our collective by the measure of the re-
lative renal recovery (RRR). Therefore, we used the RRR of CDAA
(Table 3) as a combined measure for transdermal penetration and
systemic metabolism, but the RRR did not differ among sex groups or
different skin types.
3.1. Strength and limitations
Our study was performed with the objective to describe and quan-
tify potential systemic availability and urinary excretion of nowadays
commonly used organic UV-filters after dermal application of a sunsc-
reen under real-life conditions. Such kinetic data should enable sound
exposure assessment to be used in risk assessment. From this back-
ground, some limitations need to be discussed.
First, the creatinine levels in some urine samples fell short of the
desired range of 0.3–3.0 g/L urine (WHO, 1996). This was probably
caused by the high overall beverage consumption due to hot weather.
However, we adjusted for diuresis induced variation by using creati-
nine-based urine concentrations. Additionally, subjects with very high
urine volumes in the course of the initial 24 h were excluded from
analysis.
Second, a potential oral co-exposure with UV filters through hand-
Table 3
Urinary concentrations and kinetics of avobenzone (AVO), octocrylene (OC) and its metabolite CDAA.
AVO OC CDAA
Median Min–Max Median Min–Max Median Min–Max
Concentration at t0 [μg/g crea] < LOD <LOD <LOD <LOD 22.0 0.2–185.4
Max. observed concentration [μg/g crea] 3.4 < LOD–25.2 9.6 < LOD–91.4 2072.4 1127.9–5207.2
Concentration at 166 h [μg/g crea] < LOD <LOD <LOD <LOD 136.0 36.9–278.9
Cumulative excretion over 24 h [μg], est. n.d. n.d. 1630 1087–4761
RRR of applied parent substance [%] n.d. n.d. 0.029 0.018–0.086
tmax [h] n.d. n.d. 15.9
(95% CI: 15.2–16.7)
kel [h-1] n.d. n.d. 0.018
(95% CI: 0.017–0.020)
Half-life t1/2 [h] n.d. n.d. 37.7
(95% CI: 35.1–40.4)
Samples below LOD [%] 87 81 1
LOD [μg/L] 1.5 1.44 0.45
n.d.= not determinable; crea= creatinine; LOD= limit of detection; RRR= relative renal recovery; Min=minimum; Max=maximum; t= time point;
tmax= time of peak concentration after first application; est.= estimated.
Fig. 3. Comparison of kinetic log-normal plasma models of octocrylene in plasma and its metabolite CDAA in plasma (left y-axis) and urine (right y-axis) on log10-
transformed concentration scales. The respective times of peak concentrations are indicated by dotted vertical lines.
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mouth contamination or swallowing of sunscreen-contaminated sweat
cannot be dismissed completely. However, the primary route of sys-
temic exposure was presumably via dermal penetration as we took
precautions (sparing of eyes and lips, use of cutlery) as described above.
This said, food-consumption during recreational or occupational out-
door activities will inevitably cause some hand-mouth contamination
and therefore would even reflect a realistic additional exposure sce-
nario. The plasma and urine profiles found in our study, actually,
clearly demonstrate primarily dermal uptake and elimination process
and do not suggest a relevant share of oral uptake in comparison with
the pharmacokinetic data after oral dosage from previous studies (Bury
et al., 2018, 2019).
Third, external exposure with the sunscreen was terminated about
9 h after the first application when the study subjects were requested to
take a shower, although the efficiency of the cleaning procedure was
not checked. Furthermore, exposure to sunlight (UV) and heat stopped
after 8.5 h. Thus, elevated skin temperature and a possibly enhanced
regional cutaneous blood flow influencing the drainage from a skin
reservoir should exert less effect thereafter. Furthermore, the proximity
of the OC and AVO plasma levels to the detection limits of our methods
should be critically discussed, although levels showed plausible profiles
over time. However, the resulting uncertainty in the calculation ap-
proach for the kinetic model and the half-life period for OC in plasma
has to be acknowledged. Owing to an increasing number of samples
below the LOD in the follow-up (5% after 24 h, 25% after 48 h and 30%
after 72 h) and their replacement by one half of the LOD, the calculation
of the half-life period faces some uncertainties. Thanks to a better data
basis (without any samples under the LOD in the follow-up) this con-
sideration becomes less relevant for CDAA in plasma and urine.
Nevertheless, the pharmacokinetic results should be regarded as ex-
ploratory. For CDAA the follow-up period did not include the return to
baseline levels, therefore comparison of the AUCs slightly overestimates
the 24 h fraction in respect to the overall excretion. However, due to the
far advanced elimination process after 7 days and the robust elimina-
tion data in the respective relevant timeframes thereof, this should not
substantially influence the time to peak concentration or the half-life.
For AVO in plasma the rather high LOD of our method in comparison
with the measured concentrations (highest concentration detected ~10-
fold above the LOD) constitutes a limiting factor and led to several
subjects without any quantifiable samples. Finally, the pharmacokinetic
characteristics (peak time, t1/2) were not determined for a single bolus
application but for multiple dermal applications over one day.
Therefore, t1/2 is not a simple unidirectional reflection of the elimina-
tion of the systemic burden as a delayed afflux of analytes from (sub)
cutaneous reservoirs into the circulatory systems overlaps with its
elimination.
Some important strengths should be pointed out as well. Ex-vivo
studies may indicate the ability of dermal penetration of UV filters, but
do not provide a valid exposure representation, enabling risk assess-
ment, like the present in vivo study. Comparing our data with those of
the existing in-vivo studies after dermal application of sunscreens, one
important advantage of the present study is the simultaneous de-
termination of the organic UV filter OC along with its metabolite CDAA
in plasma and urine. While the study design does not allow acquiring
the overall burden fully due to other possible elimination routes (e.g.
feces) and possible deposition in body fat tissue, the simultaneous
analyte determination in blood and urine allows a better understanding
of the metabolism and elimination pathways. Additionally, we mi-
micked real-life exposure conditions as closely as possible and eval-
uated the kinetics in a reasonably sized collective. With 20 volunteers,
our kinetic profiles are likely to represent the common elimination
timeline and allowed a meaningful calculation of time to peak con-
centration and terminal half-life. The strong correlation between
plasma and urine CDAA concentrations during the exposure period
supports the reliability of the analytical methods applied. Lastly, by
means of our study design with complete fractional urine sampling over
the first 24 h, we could determine the total excreted amounts during the
first day independent of creatinine or dilution effects greatly enhancing
the validity of study results.
4. Conclusion
The results of the present study demonstrate a considerable trans-
dermal penetration of AVO and OC after real-life sunscreen application.
The combined monitoring of parent compound and metabolite was
crucial for revealing the extent of bioavailability of OC via the dermal
route. On the other hand, the high internal load of the specific meta-
bolite CDAA which was found in our study calls for toxicological safety
evaluation dedicated to this substance particularly. In-vitro studies fo-
cusing on toxic effects of the original active ingredient, that is OC, could
miss specific effects of CDAA that might exist, due to a lack of in-vivo
metabolism. Similar concerns exist with respect to AVO. Furthermore,
additional studies exploring the nature and extent of a possible extra-
hepatic metabolism, most notably a dermal metabolism, and its com-
parison with hepatic metabolism pathways would greatly expand ex-
isting knowledge. Depot formation and potential bioaccumulation in
humans from multiday exposure is very likely for OC and AVO in view
of the toxicokinetic data, its extent however is still questionable. A
recent study on plasma concentrations of active sunscreen ingredients
under maximum use conditions demonstrated pharmacokinetic plasma
Fig. 4. Comparison of CDAA plasma and urine concentrations at different sampling times.
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profiles consistent with drug accumulation for AVO and OC (Matta
et al., 2019). However, as the former study did not include metabolites
or urinary excretion, the extent of such potential accumulation remains
largely uncharted. It is also conceivable that saturation effects e.g. via
intradermal depot formation come into effect, limiting further uptake
within a rather short period of time like 2 to 3 days. In conclusion,
further studies to extend the knowledge on accumulation effects are
needed.
On a final note, although the application of sunscreens is common
practice around the world (Mancuso et al., 2017; Seite et al., 2017), the
evidence regarding preventive effectiveness and safety of these pro-
ducts is less conclusive (Krause et al., 2012; Bens, 2014; Young et al.,
2017; Silva et al., 2018). On the other hand, adverse health effects and
potential toxicity of organic UV filters have been discussed con-
troversially repeatedly (Gilbert et al., 2013; de Groot and Roberts,
2014; Wang et al., 2016; Ruszkiewicz et al., 2017; Ahn et al., 2019). So
far no limit values for actual human biomonitoring data have been
established that could be used in the light of potential toxicological
effects. As this study provides further insight into the systemic avail-
ability and human load of several organic UV filters following a dermal
application, those safety concerns should be further addressed. In par-
ticular, as the application of sunscreens or use of organic UV filters in
various cosmetic products for photoprotective measures is currently
abundant throughout the industrialized world.
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